巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Dynavax Technologies Corp

    DVAX
    14.230
    1.390
    8.90%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Dynavax Technologies Corp - 延遲價格・最後更新於 16/08 9:30
    最高位
    15.400
    最低位
    14.050
    開市價
    --
    前收市價
    15.620
    成交量(千)
    303.14
    成交額(百萬)
    36.75
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    1,799.72
    市盈率
    8.840
    息率
    --
    差價
    --
    52週高低
    21.390 - 7.260
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Dynavax Technologies Corp
    證券代碼
    DVAX.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product.
    發行量
    124921757
    公司總部
    2100 Powell Street, Suite 900
    公司網址
    https://www.dynavax.com
    公司電郵
    narndt@dynavax.com
    公司電話
    +1 510 848-5100
    暫無內容

    關於

    Dynavax Technologies Corp(DVAX.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product.
    詳細公司背景可參考: https://www.dynavax.com